[Austrian guidance for the pharmacologic treatment of osteoporosis in postmenopausal women: Addendum 2010].

Abstract

The Austrian Society for Bone and Mineral Research routinely publishes evidence-based guidelines for the treatment of postmenopausal osteoporosis. The fully human monoclonal antibody denosumab (Prolia(®)) has been recently approved by the European Medical Agency (EMEA) and the Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis. Denosumab has been shown to reduce vertebral, non-vertebral,and hip-fracture risk effectively. Together with alendronate, risedronate, zoledronate, ibandronate, strontium ranelate, and raloxifene, denosumab constitutes an effective option in the treatment of postmenopausal osteoporosis.

• Authors: Hans Peter Dimai, Peter Pietschmann, Heinrich Resch, Elisabeth Preisinger, Astrid Fahrleitner-Pammer, Harald Dobnig, Klaus Klaushofer, Austrian Society for Bone and Mineral Research (AuSBMR)
• Journal: Wiener medizinische Wochenschrift (1946) (Wien Med Wochenschr) Vol. 160 Issue 21-22 Pg. 586-9 (Dec 2010) ISSN: 1563-258X [Electronic] Austria
• Vernacular Title: Österreichischer Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose: Addendum 2010.
• PMID: 21170699 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Bone Density Conservation Agents
• RANK Ligand
• Denosumab

Topics

• Antibodies, Monoclonal (adverse effects, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Bone Density Conservation Agents (adverse effects, therapeutic use)
• Denosumab
• Drug Approval
• Europe
• Evidence-Based Medicine
• Female
• Fractures, Spontaneous (prevention & control)
• Humans
• Osteoporosis, Postmenopausal (drug therapy)
• RANK Ligand (adverse effects, therapeutic use)